Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
Cart
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Home
Journals
Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
Open Access
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights
Xing Li
Xing Li
,
Kaida Liu
Kaida Liu
,
Lidong Xing
Lidong Xing
and
Boris Rubinsky
Boris Rubinsky
| Sep 04, 2023
Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
About this article
Previous Article
Next Article
Abstract
Article
Figures & Tables
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Article Category:
Review
Published Online:
Sep 04, 2023
Page range:
279 - 291
Received:
Jul 20, 2023
Accepted:
Aug 04, 2023
DOI:
https://doi.org/10.2478/raon-2023-0044
Keywords
tumor treating fields
,
clinical applications of TTFields
,
mechanisms of action of TTFields
© 2023 Xing Li et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
The process of TTFields clinical trials on typical tumor types.
FIGURE 2.
Clinical trials of TTFields treatment on glioblastoma multiforme (GBM)EF-11= controlled randomized phase III trial EF-11; EF-14 = phase III trial EF-14; OS = overall survival; PFS = progression-free survival; TMZ = temozolomide
FIGURE 3.
Clinical trials of TTFields treatment on malignant pleural mesothelioma and non-small cell lung cancer (NSCLC).EF-15 phase I/II = clinical trial NCT00749346; LUNAR = clinical trial NCT02973789; OS = overall survival; PFS = progression-free survival; STELLAR = clinical trial NCT 02397928
FIGURE 4.
Clinical trials of TTFields treatment on platinum-resistant ovarian cancer (PROC), pancreatic adenocarcinoma (PAC) and hepatocellular carcinoma (HCC).AEs = adverse events; INNOVATE = a phase I/II clinical trial (EF-22, NCT02244502) and a phase III randomized controlled clinical trial (EF-28, NCT03940196); OS = overall survival; QoL = quality of life (QoL); PANOVA = a phase I/II clinical trial (EF-20, NCT01971281) and a larger randomized clinical phase III (EF-27, NCT03377491); PFS = progression-free survival
FIGURE 5.
Researches on potential mechanisms of TTFields action.